Literature DB >> 31102296

Mucous membrane pemphigoid and oral blistering diseases.

B Carey1, J Setterfield1,2,3.   

Abstract

The autoimmune blistering disorders present with variable frequency in the oral cavity. Recognition of their key clinical features at presentation is important, as there are many causes of oral ulceration. Careful history-taking, clinical examination, an understanding of pathogenesis and appropriate investigations are essential. With the exception of the rare genodermatoses that may lead to blistering and oral ulceration, the majority of patients have an acquired disorder. These include the rare autoimmune blistering diseases mucous membrane pemphigoid (MMP), pemphigus vulgaris (PV), linear IgA disease, epidermolysis bullosa acquisita and paraneoplastic pemphigus. Important clinical differential diagnoses include erythema multiforme, which may be mistaken for PV in appearance, while oral lichen planus may be indistinguishable from MMP. Angina bullosa haemorrhagica may also present with tense haemorrhagic bullae, and in the absence of diagnostic tests, requires an astute clinical diagnosis based upon the history. Newer laboratory techniques have facilitated identification of target antigens and epitopes in the autoimmune blistering diseases, particularly in MMP. Current interest is in whether these relate to clinical presentation and outcomes. There have also been recent investigations into the use of saliva as an alternative medium to serum for the diagnosis of oral vesiculobullous lesions. Assessment of disease severity and measurement of quality of life at presentation and subsequent follow-up is paramount to interpreting therapeutic response. Furthermore, combining these scores with serological and/or salivary biomarkers is valuable in the assessment of clinical response. In this paper, we discuss MMP and its important differential diagnoses.
© 2019 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2019        PMID: 31102296     DOI: 10.1111/ced.13996

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  7 in total

Review 1.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

2.  Oral mucous membrane pemphigoid in a group of Thai patients-A 15-year retrospective study.

Authors:  Waranun Buajeeb; Kununya Pimolbutr; Naruemon Panpradit; Nis Okuma
Journal:  J Dent Sci       Date:  2021-11-24       Impact factor: 3.719

Review 3.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

4.  Mucous membrane pemphigoid in a patient with chronic hepatitis B virus infection: A case report.

Authors:  Christine Yi-Ting Chou; Chi-Wei Lin; Gwo-Shing Chen; Ru-Yi Huang
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

5.  Autoimmune Disease Classification Based on PubMed Text Mining.

Authors:  Hadas Samuels; Malki Malov; Trishna Saha Detroja; Karin Ben Zaken; Naamah Bloch; Meital Gal-Tanamy; Orly Avni; Baruh Polis; Abraham O Samson
Journal:  J Clin Med       Date:  2022-07-26       Impact factor: 4.964

Review 6.  Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.

Authors:  Maja Ptasiewicz; Dominika Bębnowska; Paulina Małkowska; Olga Sierawska; Agata Poniewierska-Baran; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Renata Chałas
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

7.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.